Patent · US Active

Compositions and methods for inhibiting expression of transthyretin

US8168775B2 · kind B2 · utility

34Cited by

1References

23Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Dinah Wen-Yee Sah · Boston, US
Gregory Hinkle · Plymouth, US
Rene Alvarez · Boxborough, US
Stuart Milstein · Cambridge, US
Qingmin Chen · Wuxi, CN

Key dates

Filing date	Oct 20, 2009
Grant date	May 1, 2012
Priority date	—
Expiry date	Oct 20, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.